AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management - Trial NCT06376851
Access comprehensive clinical trial information for NCT06376851 through Pure Global AI's free database. This phase not specified trial is sponsored by HeartFlow, Inc. and is currently Enrolling by invitation. The study focuses on Coronary Artery Disease. Target enrollment is 10000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
AI-enabled quantitative coronary plaque analysis (AI-QCPA)
Observational
diagnostic test
Sponsor & Location
HeartFlow, Inc.
Timeline & Enrollment
N/A
Mar 27, 2024
Mar 27, 2030
Primary Outcome
Primary Endpoint
Summary
The objective of HeartFlow's DECIDE Registry is to collect observational data about the
 management of patients before and after HeartFlow Artificial Intelligence-Quantitative
 Coronary Plaque Analysis (AI-QCPA).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06376851
Non-Device Trial